COGT · CIK 1622229
What Cogent Biosciences, Inc. told the SEC could break it.
Cogent's register is built around a single drug candidate and the fragility of supporting it. Its lead program, bezuclastinib, relies on single-source third parties for both its active ingredient and finished drug product, with no qualified alternatives — so losing any one supplier could set back development just as it pursues FDA approval. Still pre-revenue, the company posted a $328.9 million net loss in 2025 against a $1.19 billion accumulated deficit, leaving it dependent on continued capital raises (including an up-to-$300 million ATM facility); and it leans on third-party R&D vendors, some based in China, exposing its discovery work to trade-war, export-control and political disruption.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Sole-source dependency
- Single-source API & drug product for bezuclastinibhigh
The active pharmaceutical ingredient and drug product for its lead candidate bezuclastinib are supplied by single-source third parties with no qualified alternates, so loss of any of these suppliers could significantly harm development and supply just as it pursues FDA approval.
“The third parties upon whom we rely for the supply of the API and drug product used in bezuclastinib are our sole source of supply, and the loss of any of these suppliers could significantly harm our business.”
SEC filing →As of 2026
Liquidity & debt
- Pre-revenue capital dependencemedium
No approved products or product revenue; net loss was $328.9M in 2025 against a $1,188.4M accumulated deficit, so the company depends on continued capital raises (e.g., an up-to-$300M ATM facility) to fund development.
“Our net loss was $328.9 million for the year ended December 31, 2025 compared to net loss of $255.9 million for the year ended December 31, 2024. As of December 31, 2025, we had an accumulated deficit of $1,188.4 million.”
SEC filing →As of 2026
Regulatory & policy
- China-based third-party R&D vendors / trade-war exposuremedium
Cogent depends on third-party vendors and collaborators — including certain parties located in China — to support research, discovery and pipeline expansion, exposing it to disruption from trade war, political unrest, export controls or local events affecting those China-based providers.
“We also rely on third-party vendors and collaborators to support our research and discovery efforts and to help expand our drug candidate pipeline, including certain third parties located in China, and we expect to continue to use such third parties.”
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch